Practical Approaches to the Complex World of HCV
Thank you for joining us for this CME/CE Webcast, Profiles in CML: Case-Based Approaches to Managing Resistance and Improving Outcomes.
This CME/CE program will include a brief pretest. Please start now by answering these 4 questions:

1.The ____ mutation(s) that confer(s) resistance to imatinib, dasatinib, and nilotinib is(are):
T315I
E255K
Both T315I and E255K
2.The most common cause of imatinib resistance is:
Decreased drug exposure
BCR-ABL amplification and increased expression
Mutations in BCR-ABL kinase domain
3.When deciding between dasatinib and nilotinib as salvage therapy for patients with imatinib failure, a pre-existing bleeding disorder or the need for ongoing anticoagulation or antiplatelet therapy suggests that _____ would be an appropriate choice.
Nilotinib
Dasatinib
Neither nilotinib nor dasatinib
4.How often do you currently use each of the following patient care strategies?
  Always Very Often Sometimes Not Very Often Never N/A
Utilize qPCR after 3 months of therapy to predict a patient’s ability to achieve a subsequent major molecular response
Utilize criteria established by the European LeukemiaNet Consensus to determine treatment failure or suboptimal response to therapy
Utilize BCR-ABL mutation analysis to determine the most appropriate therapy